Jefferies Keeps Optimer (OPTR) at Buy as CEO Makes Plans For Growth
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Jefferies maintained a Buy rating on Optimer Pharmaceuticals (NASDAQ: OPTR), a company that focuses on the discovery, development and commercialization of anti-infective products, with one marketed drug for the treatment of diarrhea, DIFICID (fidaxomicin/OPT-80).
"While preannounced 3Q12 gross Dificid sales of $18.4M (~+2% q/q) are soft, OPTR's new strategy to drive further Dificid growth is reassuring," said analyst Eun K. Yang.
To address Dificid cost issues and enable patient access, Optimer Pharmaceuticals CEO offered a new strategy, including a 25 percent discount to acute care hospitals, New Technology Add-On Payment, and a Dificid Rx Assist program.
Jefferies cut its price target on Optimer to $16.00 (from $17.00) to reflect revised U.S. sales and EU royalties.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $11.46 yesterday.
"While preannounced 3Q12 gross Dificid sales of $18.4M (~+2% q/q) are soft, OPTR's new strategy to drive further Dificid growth is reassuring," said analyst Eun K. Yang.
To address Dificid cost issues and enable patient access, Optimer Pharmaceuticals CEO offered a new strategy, including a 25 percent discount to acute care hospitals, New Technology Add-On Payment, and a Dificid Rx Assist program.
Jefferies cut its price target on Optimer to $16.00 (from $17.00) to reflect revised U.S. sales and EU royalties.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $11.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
